Elevated CDC7 and MCM helicase expression levels in these cell models, especially the CDC7 direct target MCM2 subunit, correlate with higher proliferative rates observed in clinical prostate cancer with disease progression. This evidence concerns the gene MCM2 and prostate carcinoma.